Soleno Therapeutics, Inc.

Ticker SLNO

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

1-10 Employees
Based in Redwood City, California

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.

Visit website

REPORT RATINGS

4.8 / 5.0 (111)

Soleno Therapeutics, Inc. reports have an aggregate usefulness score of 4.8 based on 111 reviews.

Soleno Therapeutics, Inc.